OM1

Altis Labs Raises US $6 Million in Seed Funding Co-Led by Debiopharm and Benchstrength to Advance AI Platform for Clinical Trials

Retrieved on: 
Wednesday, June 21, 2023
Software, Research, Radiology, Pharmaceutical, Data Management, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, Medicine, Partnership, OM1, American Society of Clinical Oncology, Clinical trial, Cancer, Bayer, Translation, Journal, Translational medicine, MD, Patient, Debiopharm, Informatics, Chairperson, Artificial intelligence, Entrepreneurship, AI, Society, Economics, Cryptocurrency, Medical imaging, Pharmaceutical industry, Medical device

Altis Labs, Inc. (“Altis”), the computational imaging company accelerating clinical trials with artificial intelligence, today announces the closing of its US $6 million seed financing.

Key Points: 
  • Altis Labs, Inc. (“Altis”), the computational imaging company accelerating clinical trials with artificial intelligence, today announces the closing of its US $6 million seed financing.
  • “We are thrilled to partner with Benchstrength and Debiopharm,” said Felix Baldauf-Lenschen, Co-Founder and CEO of Altis.
  • Altis was founded with the belief that imaging is the richest source of clinical data but is vastly underutilized.
  • Funding will be used to scale the development of Nota, Altis’ AI-powered imaging biomarker platform, across solid tumor types and therapeutic areas.

OM1 Launches Analytics to Deliver Mental Health & Immunology Insights on Prescriber Trends and Therapy Effectiveness

Retrieved on: 
Wednesday, May 24, 2023
Science, Research, Pharmaceutical, Health, Mental Health, Artificial Intelligence, Health Technology, Technology, Cloud, RFD, Analytic, OM1, Prescription, Geography, Doctor of Science, MD, Patient, Drug development, Nursing

OM1 , a leading real-world data, outcomes, and technology company with a focus on chronic conditions, today announced the launch of two new Real-World Analytics products – Prescriber Trends and Comparative Outcomes – to provide standardized, ready-to-access analyses of trends in treatment and outcomes in immunology and mental health condition areas.

Key Points: 
  • OM1 , a leading real-world data, outcomes, and technology company with a focus on chronic conditions, today announced the launch of two new Real-World Analytics products – Prescriber Trends and Comparative Outcomes – to provide standardized, ready-to-access analyses of trends in treatment and outcomes in immunology and mental health condition areas.
  • A combination of market trends – an emphasis on personalized medicine, the rise of new modalities and treatment options, and regulatory challenges – means that pharmaceutical companies are constantly amending commercial strategies to keep up.
  • The healthcare landscape continues to evolve, but one thing remains constant – the need for deep, actionable, and data-backed insights.
  • Comparative Outcomes: leverages extensive patient outcomes data extracted from unstructured clinical notes to provide information on the effectiveness and comparative effectiveness of medications across various outcomes over time.

OM1 Doubles Lupus Dataset, Representing More Than 56,000 Patients Prospectively Followed With Deep Clinical Data

Retrieved on: 
Wednesday, May 10, 2023
Technology, Research, Clinical Trials, Health Technology, Health Insurance, Health, General Health, Science, Artificial Intelligence, Lupus Foundation of America, OM1, Woman, SLE, Lupus, CLE, Data, Patient, Artificial intelligence, Diagnosis, Lupus nephritis, Disease, Nursing

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the expansion of its lupus dataset, PremiOM™ SLE.

Key Points: 
  • OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the expansion of its lupus dataset, PremiOM™ SLE.
  • The enhancement doubles the patient data counts to more than 56,000 Systemic Lupus Erythematosus (SLE) patients with deep clinical data and expands the OM1 Immunology Real-World Data Network to include patients with Cutaneous Lupus Erythematosus (CLE) and Lupus Nephritis.
  • The dataset enables faster, more cost-effective access to research-grade lupus data for understanding, comparing, and predicting treatment outcomes for patients.
  • OM1 is proud to be building unique data assets and solutions focused on unlocking patient insights,” said Gary Curhan, Chief Medical Officer at OM1.

OM1 Unveils Patented, AI-powered Platform to Accelerate Personalized Medicine

Retrieved on: 
Thursday, April 13, 2023
Health, Technology, Health Technology, Artificial Intelligence, Software, Clinical trial, AI, OM1, HIV disease progression rates, Research, Patient, Population health, Phenom, Risk, Nursing, Medical imaging

OM1 , a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™ , its artificial intelligence-powered platform for personalized medicine.

Key Points: 
  • OM1 , a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™ , its artificial intelligence-powered platform for personalized medicine.
  • PhenOM powers personalized healthcare insights at scale across the entire healthcare ecosystem, from life science research to point-of-care clinical decision making.
  • “Most people have now heard of the promise of AI through GPT-4, but we still have not seen many really mature, real-world clinical applications using advanced language models,” said Dr. Joseph Zabinski, Managing Director of AI & Personalized Medicine at OM1.
  • “PhenOM is groundbreaking technology because it uses AI to translate actionable insights from our highly enriched datasets and phenotyping technology into opportunities for more personalized healthcare.

OM1 Expands Mental Health Offering With Real-World Datasets Including Schizophrenia and Bipolar Disorder

Retrieved on: 
Thursday, March 2, 2023
General Health, Health Technology, Health, Mental Health, Depression, Overalls, FDA, Research, Schizophrenia, Pharmacy, Mental health, Patient, Anxiety, DSM-IV codes, Mental, HIV disease progression rates, OM1, Bipolar, Mental Health Research Institute (Melbourne), Data, Bipolar disorder, Nursing, Neuroscience

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Health and Neuroscience Real-World Data to include schizophrenia and bipolar disorder.

Key Points: 
  • OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Health and Neuroscience Real-World Data to include schizophrenia and bipolar disorder.
  • By introducing enhanced data from more than 148,000 patients with schizophrenia and bipolar, OM1 paves the way for unmatched clinical depth and novel research insights.
  • The data is part of the larger OM1 Mental Health Network of more than 3 million patients, making it the largest specialty network of its kind in the U.S.
  • To learn more about the largest Mental Health and Neuroscience data network in the U.S., please email [email protected] .

OM1 Launches Analytic Reports Uncovering Causes of Medication Discontinuation in Immunology Patients

Retrieved on: 
Thursday, February 2, 2023
Research, Technology, Clinical Trials, Health Technology, Managed Care, Pharmaceutical, Health, Data Management, Science, Other Science, Psoriatic arthritis, Physician, Rheumatoid arthritis, Patient, Depression, Schizophrenia, Atopic dermatitis, Bipolar disorder, OM1, RFD, Reason (argument), Conditional sentence, Contraindication, Psoriasis, Ankylosing spondylitis, MD, Pharmaceutical industry, Dermatology

OM1 a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its Reasons for Discontinuation (RfD) Analytic Reports.

Key Points: 
  • OM1 a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its Reasons for Discontinuation (RfD) Analytic Reports.
  • Leveraging the OM1 Real-World Data CloudTM , Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports contain highly valuable, difficult-to-obtain medication discontinuation trends for bDMARDs, cDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions.
  • Understanding discontinuation patterns in patients is critical so that pharmaceutical companies can act on insights related to tolerability, costs, and emerging contraindications to improve the patient experience.
  • To learn more about the Reasons for Discontinuation (RfD) Reports and other custom analyses available, please email [email protected] .

OM1 ENHANCES GASTROENTEROLOGY CAPABILITIES WITH PREMIUM REAL-WORLD DATASETS FOR ULCERATIVE COLITIS & CROHN'S DISEASE

Retrieved on: 
Wednesday, September 14, 2022
Psoriatic arthritis, Crohn's disease, Database, OM1, CDAI, Inflammation, Extrapyramidal system, Multiple sclerosis, Mayo, Depression, Heart failure, Patient, CD, Inflammatory bowel disease, Pain, Psoriasis, Ankylosing spondylitis, Data, Diagnosis, Ulcerative colitis, Rheumatoid arthritis, UC, Atopic dermatitis, Research, IBD, SLE, Axial spondyloarthritis, Conditional sentence, Medical imaging, Medical device, Disease

BOSTON, Sept. 14, 2022 /PRNewswire/ -- OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its PremiOM™ Ulcerative Colitis (UC) and Crohn's Disease (CD) datasets, providing comprehensive, clinically-deep and representative data to support a broad assortment of research needs.

Key Points: 
  • UC and CD are the two main types of Inflammatory Bowel Disease (IBD), which affect up to 3 million people in the U.S. alone.
  • UC and CD are lifelong conditions that cause chronic inflammation in the intestines, leading to pain and a variety of symptoms in those affected.
  • The OM1 PremiOM UC and CD datasets look to support these research efforts.
  • The OM1 UC and CD datasets join a growing suite of OM1 PremiOM datasets in chronic diseases , including Depression, Multiple Sclerosis, Heart Failure, Atopic Dermatitis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Ankylosing Spondylarthritis (AxSpA), and more.

OM1 LAUNCHES A NEW ESTIMATION MODEL FOR THE EXPANDED DISABILITY STATUS SCORE (EDSS) FOR MULTIPLE SCLEROSIS PATIENTS

Retrieved on: 
Thursday, June 23, 2022
Cloud, Depression, Autoimmunity, Inflammation, Patient, Mental health, Hypoesthesia, Data set, Diagnosis, Expanded Disability Status Scale, Paper, CNS, Time, Multiple sclerosis, Fatigue, RWD, Research, Machine learning, Muscle weakness, MLP, Multiple Sclerosis Journal, EDSS, Lists of diseases, OM1, Conditional sentence, Spasticity, Severe cognitive impairment, Dizziness, MS, Database, SAGE Publishing, Central nervous system, Pharmaceutical industry, Medical imaging

BOSTON, June 23, 2022 /PRNewswire/ -- OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by Sage Publications.

Key Points: 
  • Scores can help determine the course of illness, need for different levels of care, and help guide treatment decisions.
  • Nearly 1 million Americans suffer from MS. With no cure, delay in diagnosis and treatment can result in permanent disability.
  • Once diagnosed, clinicians use the Expanded Disability Status Score (EDSS) to evaluate and measure disability levels in MS patients.
  • For this study, OM1 extrapolated data from the OM1 PremiOM MS Dataset to amplify and expand existing clinician rated EDSS scores.

Five Leading Real-World Data and Analytics Organizations Join the RWE Alliance, Doubling Membership

Retrieved on: 
Tuesday, April 5, 2022
Data Management, White House, Federal Government, Public Policy, Government, Health, Technology, Practice Management, Software, Organization, Syneos Health, Cancer Breakthroughs 2020, Pandemic, Alliance, Covington & Burling, OM1, Administration, Policy, RWD, FDA, Patient, RWE, Medical device, IQVIA, Tempus

The RWE Alliance is a policy and advocacy coalition of real-world data (RWD) and analytics organizations with a common interest in harnessing the power of RWE to inform regulatory decision making to improve patients lives.

Key Points: 
  • The RWE Alliance is a policy and advocacy coalition of real-world data (RWD) and analytics organizations with a common interest in harnessing the power of RWE to inform regulatory decision making to improve patients lives.
  • The founding members of the Alliance are Aetion , Flatiron Health , IQVIA , Syapse , and Tempus .
  • We are a coalition of real-world data (RWD) and analytics organizations with a common interest in harnessing the power of real-world evidence (RWE) to inform regulatory decision making to improve patients lives.
  • Our members have deep knowledge and experience working with healthcare data across disease areas and patient populations, and we aim to bring these collective insights to bear in support of RWE policies.

OM1 LAUNCHES NEW MENTAL HEALTH AND NEUROSCIENCE REAL-WORLD DATA NETWORK

Retrieved on: 
Thursday, March 31, 2022
Multiple sclerosis, Bipolar disorder, Mental health, Government, HIV disease progression rates, Massachusetts General Hospital, Central nervous system, CNS, Research, Faculty, Lists of diseases, Hospital, OM1, CEO, National Institutes of Health, Health, Psychiatry, Schizophrenia, Artificial intelligence, Industry, Technology, Mental, National, MS, Harvard Medical School, Mental Health Research Institute (Melbourne), Central nervous system disease, Depression, FDA, Patient, Medicine, Pharmaceutical industry, Medical device, Neuroscience

Real-world data with clinical depth and nuance are critically needed to understand disease progression, patient characteristics, condition subtypes and variations -- as well as the costs and clinical outcomes of new and existing treatments. These data are now available from OM1 to be used to accelerate medical research and FDA approvals of new therapies and to help partners deliver the right treatment for the right patients at the right time.

Key Points: 
  • With over 9,000 specialists and 3M patients, the OM1 Mental Health Data Network is one of the largest in the country.
  • Mental health and CNS disorders are areas of unmet and growing medical need in the U.S.
  • In particular, mental health disorders have been exacerbated by the pandemic and now constitute a national crisis.
  • The Mental Health and Neuroscience Specialty Area will allow OM1 to have unparalleled focus on data-driven solutions to help life sciences companies, payers, providers, and government agencies.